Positions

Overview

  • Steven M. Rowe was born in Baton Rouge, LA in May 1972. He received his BA degree from the University of Virginia in 1994, his medical degree from Vanderbilt University in 1998, and an MSPH from the University of Alabama at Birmingham in 2005. He completed a combined Internal Medicine and Pediatrics internship and residency at the University of Alabama at Birmingham. He also completed a combined Pulmonary and Critical Care Medicine and Pediatric Pulmonary fellowship at the University of Alabama at Birmingham.
    In 2014, Dr. Rowe was promoted to Professor with tenure in the Departments of Medicine (Pulmonary, Allergy, and Critical Care Medicine), Pediatrics (Pediatric Pulmonology), and Cell Developmental and Integrative Biology. He is the Director of the Gregory Fleming Cystic Fibrosis Research Center, which involves over 100 faculty members and has been continuously funded for over 25 years. Dr. Rowe is board certified in Internal Medicine, Pediatrics, Pulmonary Medicine and Critical Care Medicine and serves as a Special Consultant for Translational Science for the Cystic Fibrosis Foundation.
    Dr. Rowe has a remarkable ability to identify, establish, and cultivate effective collaborations across institutional and geographic boundaries. He established a prolific six-year collaboration with Dr. Guillermo Tearney to advance µOCT imaging for use in respiratory epithelia to ask seminal questions in airway biology. Dr. Rowe initiated an eight-year collaboration with Dr. Mark Dransfield to investigate acquired CFTR dysfunction in COPD. He has a seven-year collaboration with Dr. David Bedwell to advance translational readthrough approaches for genetic disease. Dr. Rowe is also highly effective in research consortia. He leads the International Mucus Clearance Consortium, involving Fundamental and translational scientists. He is also a key member of the cystic fibrosis research community, helping lead the Cystic Fibrosis Therapeutics Development Network through the Center for CFTR Detection.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 Evaluation of 1,2,3-Triazoles as Amide Bioisosteres In Cystic Fibrosis Transmembrane Conductance Regulator Modulators VX-770 and VX-809Chemistry - A European Journal.  25:3662-3674. 2019
    2019 Colocolonic intussusception in an adult cystic fibrosis patientJournal of Cystic Fibrosis.  18:e11-e13. 2019
    2019 Non-obstructive vas deferens and epididymis loss in cystic fibrosis ratsMechanisms of Development.  155:15-26. 2019
    2019 Objective Versus Self-Reported Adherence to Airway Clearance Therapy in Cystic FibrosisRespiratory Care.  64:176-181. 2019
    2019 Acquired cystic fibrosis transmembrane conductance regulator dysfunction and radiographic bronchiectasis in current and former smokers: A cross-sectional studyAnnals of the American Thoracic Society.  16:150-153. 2019
    2019 CFTR modulator theratyping: Current status, gaps and future directionsJournal of Cystic Fibrosis.  18:22-34. 2019
    2019 Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutationsJournal of Cystic Fibrosis.  18:102-109. 2019
    2019 Herbal dry extract BNO 1011 improves clinical and mucociliary parameters in a rabbit model of chronic rhinosinusitisInternational Forum of Allergy and Rhinology2019
    2018 Vaporized E-Cigarette Liquids Induce Ion Transport Dysfunction in Airway Epithelia.American Journal of Respiratory Cell and Molecular Biology2018
    2018 Effect of ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis patients with G551D-CFTRJCI insight.  3. 2018
    2018 Muc5b overexpression causes mucociliary dysfunction and enhances lung fibrosis in miceNature Communications.  9. 2018
    2018 The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosisCurrent Opinion in Pharmacology.  43:152-165. 2018
    2018 Heme scavenging reduces pulmonary endoplasmic reticulum stress, fibrosis, and emphysemaJCI insight.  3. 2018
    2018 Functional anatomic imaging of the airway surfaceAnnals of the American Thoracic Society.  15:S177-S183. 2018
    2018 VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del allelesNew England Journal of Medicine.  379:1612-1620. 2018
    2018 VX-659-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del allelesNew England Journal of Medicine.  379:1599-1611. 2018
    2018 Influenza-mediated reduction of lung epithelial ion channel activity leads to dysregulated pulmonary fluid homeostasisJCI insight.  3. 2018
    2018 Ataluren, a new therapeutic for alpha-1 antitrypsin-deficient individuals with nonsense mutationsAmerican Journal of Respiratory and Critical Care Medicine.  198:1099-1102. 2018
    2018 Standardized measurement of nasal membrane transepithelial potential difference (NPD)Journal of Visualized Experiments.  2018. 2018
    2018 EMPIRE-CF: A phase II randomized placebo-controlled trial of once-daily, oral acebilustat in adult patients with cystic fibrosis – Study design and patient demographicsControlled Clinical Trials.  72:86-94. 2018
    2018 Maternal smoking induces acquired CFTR dysfunction in neonatal ratsAmerican Journal of Respiratory and Critical Care Medicine.  198:672-674. 2018
    2018 A revised airway epithelial hierarchy includes CFTR-expressing ionocytesNature.  560:319-324. 2018
    2018 Changes in lung clearance index in preschool-aged patients with cystic fibrosis treated with ivacaftor (GOAL): A clinical trialAmerican Journal of Respiratory and Critical Care Medicine.  198:526-528. 2018
    2018 An Adeno-Associated Viral Vector Capable of Penetrating the Mucus Barrier to Inhaled Gene TherapyMolecular Therapy - Methods and Clinical Development.  9:296-304. 2018
    2018 Ivacaftor-treated patients with cystic fibrosis derive long-term benefit despite no short-term clinical improvementAmerican Journal of Respiratory and Critical Care Medicine.  197:1483-1486. 2018
    2018 Seeing cilia: Imaging modalities for ciliary motion and clinical connectionsAJP - Lung Cellular and Molecular Physiology.  314:L909-L921. 2018
    2018 Sensitivity of ivacaftor to drug-drug interactions with rifampin, a cytochrome P450 3A4 inducerPediatric Pulmonology.  53:E6-E8. 2018
    2018 MicroRNA-145 antagonism reverses TGF-b inhibition of F508del CFTR correction in airway EpitheliaAmerican Journal of Respiratory and Critical Care Medicine.  197:632-643. 2018
    2018 Implementation of a successful eradication protocol for Burkholderia Cepacia complex in cystic fibrosis patientsBMC Pulmonary Medicine.  18. 2018
    2018 Not simply the lesser of two evilsAJP - Lung Cellular and Molecular Physiology.  314:L236-L238. 2018
    2018 Sinus microanatomy and microbiota in a rabbit model of rhinosinusitisFrontiers in Cellular and Infection Microbiology.  7. 2018
    2018 Development of an airway mucus defect in the cystic fibrosis ratJCI insight.  3. 2018
    2018 Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosisJournal of Cystic Fibrosis2018
    2017 Klotho Inhibits Interleukin-8 Secretion from Cystic Fibrosis Airway EpitheliaScientific Reports.  7. 2017
    2017 Tezacaftor–ivacaftor in residual-function heterozygotes with cystic fibrosisNew England Journal of Medicine.  377:2024-2035. 2017
    2017 Reduced bone length, growth plate thickness, bone content, and IGF-I as a model for poor growth in the CFTR-deficient ratPLoS ONE.  12. 2017
    2017 Toward inclusive therapy with CFTR modulators: Progress and challengesPediatric Pulmonology.  52:S4-S14. 2017
    2017 Use of ferrets for electrophysiologic monitoring of ion transportPLoS ONE.  12. 2017
    2017 Roflumilast reverses CFTR-mediated ion transport dysfunction in cigarette smoke-exposed miceRespiratory Research.  18. 2017
    2017 A multiple reader scoring system for Nasal Potential Difference parametersJournal of Cystic Fibrosis.  16:573-578. 2017
    2017 Assessment of acquired mucociliary clearance defects using micro-optical coherence tomographyInternational Forum of Allergy and Rhinology.  7:920-925. 2017
    2017 Identification of the amino acids inserted during suppression of CFTR nonsense mutations and determination of their functional consequencesHuman Molecular Genetics.  26:3116-3129. 2017
    2017 The therapeutic potential of CFTR modulators for COPD and other airway diseasesCurrent Opinion in Pharmacology.  34:132-139. 2017
    2017 Assessment of ciliary phenotype in primary ciliary dyskinesia by micro-optical coherence tomography.JCI insight.  2:e91702. 2017
    2017 Protective and antifungal properties of Nanodisk-Amphotericin B over commercially available Amphotericin B.World Journal of Otorhinolaryngology-Head and Neck Surgery.  3:2-8. 2017
    2017 Flexible, high-resolution micro-optical coherence tomography endobronchial probe toward in vivo imaging of ciliaOptics Letters.  42:867-870. 2017
    2017 A little CFTR can change a lot: slowing cystic fibrosis progressionLancet Respiratory Medicine.  5:86-87. 2017
    2017 Growth in prepubertal children with cystic fibrosis treated with ivacaftorPediatrics.  139. 2017
    2017 Lumacaftor/ivacaftor treatment of patients with cystic fibrosis heterozygous for F508del-CFTRAnnals of the American Thoracic Society.  14:213-219. 2017
    2017 A Case Report of Pregnancy During Use of Targeted Therapeutics for Cystic FibrosisJOGN nursing; journal of obstetric, gynecologic, and neonatal nursing.  46:72-77. 2017
    2017 Applying recent advances in the science of CFTR-based therapeutics to improve outcomes in patients with cystic fibrosisJournal of Cystic Fibrosis2017
    2017 Impact of CFTR modulation on intestinal pH, motility, and clinical outcomes in patients with cystic fibrosis and the G551D mutationClinical and Translational Gastroenterology.  8. 2017
    2017 The cystic fibrosis transmembrane conductance regulator potentiator ivacaftor augments mucociliary clearance abrogating cystic fibrosis transmembrane conductance regulator inhibition by cigarette smokeAmerican Journal of Respiratory Cell and Molecular Biology.  56:99-108. 2017
    2017 Therapeutic benefit observed with the CFTR potentiator, ivacaftor, in a CF patient homozygous for the W1282X CFTR nonsense mutationJournal of Cystic Fibrosis.  16:24-29. 2017
    2016 Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppressionProceedings of the National Academy of Sciences.  113:12508-12513. 2016
    2016 Discovery of clinically approved agents that promote suppression of cystic fibrosis transmembrane conductance regulator nonsense mutationsAmerican Journal of Respiratory and Critical Care Medicine.  194:1092-1103. 2016
    2016 Codon bias and the folding dynamics of the cystic fibrosis transmembrane conductance regulatorCellular and Molecular Biology Letters.  21. 2016
    2016 Increasing the endoplasmic reticulum pool of the F508del allele of the cystic fibrosis transmembrane conductance regulator leads to greater folding correction by small molecule therapeuticsPLoS ONE.  11. 2016
    2016 A ferret model of COPD-related chronic bronchitisJCI insight.  1:e87536. 2016
    2016 Particle-Tracking Microrheology Using Micro-Optical Coherence TomographyBiophysical Journal.  111:1053-1063. 2016
    2016 Dual SMAD Signaling Inhibition Enables Long-Term Expansion of Diverse Epithelial Basal CellsCell Stem Cell.  19:217-231. 2016
    2016 Pulmonary artery enlargement and cystic fibrosis pulmonary exacerbations: a cohort studyLancet Respiratory Medicine.  4:636-645. 2016
    2016 In vivo imaging of airway cilia and mucus clearance with micro-optical coherence tomographyBiomedical Optics Express.  7:2494-2505. 2016
    2016 Mutation of Growth Arrest Specific 8 Reveals a Role in Motile Cilia Function and Human DiseasePLoS Genetics.  12. 2016
    2016 Pilot evaluation of ivacaftor for chronic bronchitisLancet Respiratory Medicine.  4:e32-e33. 2016
    2016 Combination therapy with cystic fibrosis transmembrane conductance regulator modulators augment the airway functional microanatomyAJP - Lung Cellular and Molecular Physiology.  310:L928-L939. 2016
    2016 Therapeutic approaches to acquired cystic fibrosis transmembrane conductance regulator dysfunction in Chronic bronchitisAnnals of the American Thoracic Society.  13:S169-S176. 2016
    2016 New and emerging targeted therapies for cystic fibrosisBMJ.  352. 2016
    2016 Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction in Chronic Bronchitis and Other Diseases of Mucus ClearanceClinics in Chest Medicine.  37:147-158. 2016
    2016 Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftorJournal of Cystic Fibrosis.  15:67-73. 2016
    2015 Recovery of acquired cystic fibrosis transmembrane conductance regulator dysfunction after smoking cessationAmerican Journal of Respiratory and Critical Care Medicine.  192:1521-1524. 2015
    2015 Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctorsPediatric Pulmonology.  50:S3-S13. 2015
    2015 Moderate intensity exercise mediates comparable increases in exhaled chloride as albuterol in individuals with cystic fibrosisRespiratory Medicine.  109:1001-1011. 2015
    2015 Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for phe508del CFTRNew England Journal of Medicine.  373:220-231. 2015
    2015 Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: A double-blind, randomised controlled trialLancet Respiratory Medicine.  3:524-533. 2015
    2015 Cystic fibrosisNature Reviews Disease Primers.  1:15010. 2015
    2015 ▵F508 CFTR surface stability is regulated by DAB2 and CHIP-mediated ubiquitination in post-endocytic compartmentsPLoS ONE.  10. 2015
    2015 Improved clinical and radiographic outcomes after treatment with ivacaftor in a young adult with cystic fibrosis with the P67L CFTR mutationChest.  147:e79-e82. 2015
    2015 Defective innate immunity and hyperinflammation in newborn cystic fibrosis transmembrane conductance regulator-knockout ferret lungsAmerican Journal of Respiratory Cell and Molecular Biology.  52:683-694. 2015
    2015 Heme oxygenase-1-mediated autophagy protects against pulmonary endothelial cell death and development of emphysema in cadmium-treated miceAJP - Lung Cellular and Molecular Physiology.  309:L280-L292. 2015
    2015 Novel outcome measures for clinical trials in cystic fibrosisPediatric Pulmonology.  50:302-315. 2015
    2015 Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftorClinical Infectious Diseases.  60:703-712. 2015
    2014 Characterization of defects in ion transport and tissue development in Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)-knockout ratsPLoS ONE.  9. 2014
    2014 Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial dataJournal of Cystic Fibrosis.  13:139-147. 2014
    2014 Acquired defects in CFTR-dependent β-adrenergic sweat secretion in chronic obstructive pulmonary diseaseRespiratory Research.  15. 2014
    2014 Impact of heterozygote CFTR Mutations in COPD patients with Chronic BronchitisRespiratory Research.  15. 2014
    2014 A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: A phase 2 randomised controlled trialLancet Respiratory Medicine.  2:527-538. 2014
    2014 A functional anatomic defect of the cystic fibrosis airwayAmerican Journal of Respiratory and Critical Care Medicine.  190:421-432. 2014
    2014 An autoregulatory mechanism governing mucociliary transport is sensitive to mucus loadAmerican Journal of Respiratory Cell and Molecular Biology.  51:485-493. 2014
    2014 Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trialLancet Respiratory Medicine.  2:539-547. 2014
    2014 Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosisAmerican Journal of Respiratory and Critical Care Medicine.  190:175-184. 2014
    2014 Cystic fibrosis transmembrane conductance regulator activation by roflumilast contributes to therapeutic benefit in chronic bronchitisAmerican Journal of Respiratory Cell and Molecular Biology.  50:549-558. 2014
    2014 Development and maintenance of a biospecimen repository for clinical samples derived from pulmonary patientsClinical and Translational Science.  7:336-341. 2014
    2014 Evaluating the predictive ability of sweat chlorideJournal of Cystic Fibrosis.  13:118. 2014
    2014 Overcoming the cystic fibrosis sputum barrier to leading adeno-associated virus gene therapy vectorsMolecular Therapy.  22:1484-1493. 2014
    2014 Porcine nasal epithelial cultures for studies of cystic fibrosis sinusitisInternational Forum of Allergy and Rhinology.  4:565-570. 2014
    2014 Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftorAmerican Journal of Respiratory Cell and Molecular Biology.  50:805-816. 2014
    2014 The unfolded protein response affects readthrough of premature termination codonsEMBO Molecular Medicine.  6:685-701. 2014
    2013 Cigarette smoke induces systemic defects in cystic fibrosis transmembrane conductance regulator functionAmerican Journal of Respiratory and Critical Care Medicine.  188:1321-1330. 2013
    2013 Cigarette smoke induces systemic defects in cystic fibrosis transmembrane conductance regulator function.American Journal of Respiratory and Critical Care Medicine.  188:1321-1330. 2013
    2013 Cigarette smoke and CFTR: Implications in the pathogenesis of COPDAJP - Lung Cellular and Molecular Physiology.  305. 2013
    2013 Multicenter Intestinal Current Measurements in Rectal Biopsies from CF and Non-CF Subjects to Monitor CFTR FunctionPLoS ONE.  8. 2013
    2013 Cystic fibrosis chronic rhinosinusitis: A comprehensive reviewAmerican Journal of Rhinology.  27:387-395. 2013
    2013 IP-10 Is a Potential Biomarker of Cystic Fibrosis Acute Pulmonary ExacerbationsPLoS ONE.  8. 2013
    2013 Comparison of cystic fibrosis transmembrane conductance regulator (CFTR) and ciliary beat frequency activation by the CFTR modulators genistein, VRT-532, and UCCF-152 in primary sinonasal epithelial culturesJAMA Otolaryngology-Head and Neck Surgery.  139:822-827. 2013
    2013 Cystic fibrosis transmembrane regulator correctors and potentiatorsCold Spring Harbor perspectives in biology.  5. 2013
    2013 Optimizing Nasal Potential Difference Analysis for CFTR Modulator Development: Assessment of Ivacaftor in CF Subjects with the G551D-CFTR MutationPLoS ONE.  8. 2013
    2013 Cystic fibrosis transmembrane regulator correctors and potentiatorsCold Spring Harbor perspectives in medicine.  3. 2013
    2013 Cystic fibrosis transmembrane regulator correctors and potentiatorsCold Spring Harbor perspectives in biology.  5. 2013
    2013 Method for Quantitative Study of Airway Functional Microanatomy Using Micro-Optical Coherence TomographyPLoS ONE.  8. 2013
    2013 Acquired cystic fibrosis transmembrane conductance regulator dysfunction in the lower airways in COPDChest.  144:498-506. 2013
    2013 CFTR biomarkers: Time for promotion to surrogate end-point?European Respiratory Journal.  41:203-216. 2013
    2013 Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosisChest.  144:200-207. 2013
    2013 Understanding the relationship between sweat chloride and lung function in cystic fibrosisChest.  144:1418. 2013
    2012 Clearance of initial mucoid Pseudomonas aeruginosa in patients with cystic fibrosisPediatric Pulmonology.  47:1113-1122. 2012
    2012 A pharmacologic approach to acquired cystic fibrosis transmembrane conductance regulator dysfunction in smoking related lung diseasePLoS ONE.  7. 2012
    2012 Dab2 is a key regulator of endocytosis and post-endocytic trafficking of the cystic fibrosis transmembrane conductance regulatorBiochemical Journal.  441:633-643. 2012
    2012 CFTR potentiator treatment of cystic fibrosisDrugs of the future.  37:167-174. 2012
    2012 Extensive surgical and comprehensive postoperative medical management for cystic fibrosis chronic rhinosinusitisAmerican Journal of Rhinology.  26:70-75. 2012
    2012 Progress in cystic fibrosis and the CF Therapeutics Development NetworkThorax.  67:882-890. 2012
    2012 Purification of CFTR for mass spectrometry analysis: Identification of palmitoylation and other post-translational modificationsProtein Engineering -Oxford-.  25:7-14. 2012
    2012 Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutationThorax.  67:12-18. 2012
    2011 A CFTR potentiator in patients with cystic fibrosis and the G551D mutationNew England Journal of Medicine.  365:1663-1672. 2011
    2011 Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54The Clinical investigator.  89:1149-1161. 2011
    2011 Regulatory domain phosphorylation to distinguish the mechanistic basis underlying acute CFTR modulatorsAJP - Lung Cellular and Molecular Physiology.  301. 2011
    2011 Nasal potential difference measurements to assess CFTR ion channel activity.Methods in Molecular Biology.  741:69-86. 2011
    2011 Quercetin increases cystic fibrosis transmembrane conductance regulator-mediated chloride transport and ciliary beat frequency: Therapeutic implications for chronic rhinosinusitisAmerican Journal of Rhinology.  25:307-312. 2011
    2011 Medicine: A breath of fresh airScientific American.  305:48-53. 2011
    2011 A breath of fresh air.Scientific American.  305:68-73. 2011
    2010 Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutationNew England Journal of Medicine.  363:1991-2003. 2010
    2010 Activation of the cystic fibrosis transmembrane conductance regulator by the flavonoid quercetin: Potential use as a biomarker of ΔF508 cystic fibrosis transmembrane conductance regulator rescueAmerican Journal of Respiratory Cell and Molecular Biology.  43:607-616. 2010
    2010 Association of cystic fibrosis genetic modifiers with congenital bilateral absence of the vas deferensFertility and Sterility.  94:2122-2127. 2010
    2010 Cystic fibrosis transmembrane conductance regulator protein repair as a therapeutic strategy in cystic fibrosisCurrent Opinion in Pulmonary Medicine.  16:591-597. 2010
    2010 A critical role for LTA4H in limiting chronic pulmonary neutrophilic inflammationScience.  330:90-94. 2010
    2010 An international randomized multicenter comparison of nasal potential difference techniquesChest.  138:919-928. 2010
    2010 ΔF508 CFTR processing correction and activity in polarized airway and non-airway cell monolayersPulmonary Pharmacology and Therapeutics.  23:268-278. 2010
    2010 Proline-Glycine-Proline (PGP) and high mobility group box protein-1 (HMGB1): Potential mediators of cystic fibrosis airway inflammationOpen Respiratory Medicine Journal.  4:32-38. 2010
    2009 Extensive pulmonary laceration in pediatric traumaRespiration.  79:76. 2009
    2009 Pharmaceuticals targeting nonsense mutations in genetic diseases: Progress in developmentClinical immunotherapeutics.  23:165-174. 2009
    2008 Authors' responseThorax.  63:1026. 2008
    2008 Potential role of high-mobility group box 1 in cystic fibrosis airway diseaseAmerican Journal of Respiratory and Critical Care Medicine.  178:822-831. 2008
    2008 A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in Chronic neutrophilic inflammationJournal of Immunology.  180:5662-5669. 2008
    2008 Use of β blockers and the risk of death in hospitalised patients with acute exacerbations of COPDThorax.  63:301-305. 2008
    2008 Authors' responseThorax.  63:1027. 2008
    2008 Genetic and reproductive knowledge among adolescents and adults with cystic fibrosisChest.  133:1533. 2008
    2007 Bioelectric effects of quinine on polarized airway epithelial cellsJournal of Cystic Fibrosis.  6:351-359. 2007
    2007 Pulmonary aneurysms and intracardiac thrombi due to Behçet's disease in an African-American adolescent with oculocutaneous albinismClinical Rheumatology.  26:1537-1539. 2007
    2007 Restoration of W1282X CFTR activity by enhanced expressionAmerican Journal of Respiratory Cell and Molecular Biology.  37:347-356. 2007
    2007 Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trialsProceedings of the American Thoracic Society.  4:387-398. 2007
    2007 No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutationsAmerican Journal of Respiratory Cell and Molecular Biology.  37:57-66. 2007
    2006 Advances in cystic fibrosis therapiesCurrent Opinion in Pediatrics.  18:604-613. 2006
    2005 Cystic fibrosisNew England Journal of Medicine.  352:1992-2001. 2005
    2005 Cystic fibrosisNew England Journal of Medicine.  352:2039. 2005
    2002 Foodborne disease outbreaks in United States schoolsPediatric Infectious Disease Journal.  21:623-628. 2002
    2000 A foodborne outbreak of gastroenteritis associated with Norwalk-like viruses: First molecular traceback to deli sandwiches contaminated during preparationJournal of Infectious Diseases.  181:1467-1470. 2000

    Research Overview

  • Dr. Rowe specializes in developing new treatments for cystic fibrosis, the most common autosomal recessive genetic disease, and the cause of severe pulmonary disease affecting children and young adults. He founded the CF Transition Clinic for adolescents and young adults with the disease. He maintains expertise in the design and conduct of clinical trials targeting the basic CF defect. Dr. Rowe also has an interest in biomarkers of CF and other related airway diseases including measures of ion transport and the relation between mucus stasis and inflammation. He currently directs a clinical research program that examines the relationship between CF and the chronic bronchitis of COPD.

    Dr. Rowe is an accomplished academic physician scientist- a pioneer in the field of personalized therapeutics for CF, cutting-edge discovery in airway disease biology, and translational research. He is a respected authority in the design and conduct of clinical trials targeting the basic CF defect and has made key advances in the measurement and interpretation of CFTR function in humans and animals. In a related effort, Dr. Rowe has advanced both the molecular and clinical understanding of suppression of premature termination codons, representing an exciting strategy for treatment of genetic diseases caused by nonsense mutations, which are responsible for approximately 10 percent of all genetic diseases.
    Dr. Rowe has recently discovered that COPD patients exhibit acquired CFTR dysfunction through a pathway that causes delayed mucociliary clearance and confers chronic bronchitis. The approach establishes how a single gene in a rare disorder can contribute to the third leading cause of death and has lead to new efforts to evaluate CFTR modulators in patients with chronic bronchitis, potentially leading to a new paradigm for COPD treatment. Dr. Rowe co-invented one-micron resolution optical coherence tomography that captures 3D imaging in real time at the cellular level. The technique is highly sensitive to the epithelial function of airway tissues and can provide simultaneous and non-invasive measurements of the functional microanatomy of the airway surface, significantly advancing our understanding of airway disease pathogenesis.
  • Education And Training

  • Master of Science in Biostatistics, University of Alabama at Birmingham 2005
  • Doctor of Medicine, Vanderbilt University 1998
  • UAB Hospital, Internship 1999
  • UAB Hospital, Residency 2002
  • UAB Hospital, Postdoctoral Fellowship 2005
  • Full Name

  • Steven Rowe